Hematologic effects of linezolid: summary of clinical experience.
Linezolid has been associated with reversible myelosuppression. Clinical trial data were evaluated for anemia, thrombocytopenia, and neutropenia. Thrombocytopenia and a slight increased risk for anemia were evident at > or =2 weeks of linezolid treatment. Hematologic abnormalities were consistent with mild, reversible, duration-dependent myelosuppression. Appropriate monitoring is warranted with linezolid use.
Gerson
Stanton L
SL
Division of Hematology/Oncology and Ireland Cancer Center, Case Western Reserve University, University Hospitals of Cleveland, 10900 Euclid Avenue, Cleveland, OH 44106-4937, USA. slg5@cwru.edu
Kaplan
Sheldon L
SL
Bruss
Jon B
JB
Le
Vu
V
Arellano
Felix M
FM
Hafkin
Barry
B
Kuter
David J
DJ
D000081:Acetamides / Q000009:adverse effects*; D000740:Anemia / Q000097:blood* / Q000139:chemically induced*; D000890:Anti-Infective Agents / Q000009:adverse effects*; D001772:Blood Cell Count; D002986:Clinical Trials as Topic; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D000069349:Linezolid; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced; D023303:Oxazolidinones / Q000009:adverse effects*; D012189:Retrospective Studies; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced
D000081:Acetamides; D000890:Anti-Infective Agents; D006454:Hemoglobins; D023303:Oxazolidinones; D000069349:Linezolid